GlassScriptPhysician profile
Salvatore M Calandra
NPI 1659307528
$13,735.38
in general payments reported to CMS, 2019-2025
35 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,303 · 2020: $687 · 2021: $792 · 2022: $846 · 2023: $1,017 · 2024: $1,015 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,216.23 | 2019-2025 | |
| Boston Scientific Corporation | $1,493.00 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman |
| Amgen INC. | $479.01 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $468.94 | 2019-2024 | Xarelto |
| Cvrx, INC. | $446.05 | 2022-2025 | Barostim Neo System |
| Biotronik INC. | $358.99 | 2019-2023 | Biomonitor |
| E.R. Squibb & Sons, L.L.C. | $306.18 | 2021-2025 | Camzyos, Eliquis |
| Abiomed | $300.64 | 2020-2024 | Impella, Legacy |
| Edwards Lifesciences Corporation | $295.76 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.78 | 2019-2021 | |
| Abbott Laboratories | $249.93 | 2021-2025 | Jot Dx, Aveir, Freestyle Libre 3 |
| Pfizer INC. | $219.40 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.42 | 2021-2025 | Lifevest |
| Penumbra, INC. | $184.57 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $108.15 | 2022-2023 | Arcalyst |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $98.91 | 2022-2025 | Farxiga |
| Medtronic, INC. | $98.65 | 2021-2025 | Symplicity G3 |
| Regeneron Healthcare Solutions, INC. | $94.44 | 2019-2025 | Evkeeza |
| Kestra Medical Technology Services, INC. | $94.27 | 2022-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $79.59 | 2021-2024 | Nexletol |
| Medtronic Vascular, INC. | $78.33 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $71.01 | 2024-2025 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $64.64 | 2023 | Inpefa |
| Astellas Pharma US INC | $62.51 | 2021 | |
| Alnylam Pharmaceuticals INC. | $61.88 | 2022-2025 | Onpattro |
| Bridgebio Pharma, INC. | $50.69 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $49.76 | 2024-2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $48.60 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $43.77 | 2019-2022 | |
| Inspire Medical Systems, INC. | $42.96 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $39.11 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.85 | 2025 | Arexvy, Shingrix |
| Recor Medical INC | $22.05 | 2025 | Paradise Ultrasound Renal Denervation System |
| Kiniksa Pharmaceuticals International, Plc | $17.65 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $15.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Calandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.